Maraviroc Intensification in Suboptimal CD4 Recovery Study
Learn about the study design, results, and conclusions of adding Maraviroc to suppressive ART for suboptimal CD4 recovery in HIV-infected adults. The trial aimed to evaluate whether Maraviroc intensification could increase CD4 counts by at least 20 cells/mm3.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Adding Maraviroc to Suppressive ART for Suboptimal CD4 Recovery ACTG 5256
Adding Maraviroc to Suppressive ART for Suboptimal CD4 Recovery ACTG 5256: Study Design Study Design: ACTG 5256 Background: Single-arm, pilot trial of adding maraviroc to suppressive ART in setting of suboptimal CD4 recovery to evaluate whether maraviroc intensification is associated with an increase of at least 20 cells/mm3 in the CD4 count Inclusion Criteria (n = 34) - HIV-1 infected adults - Receiving stable ART with HIV RNA below limit of detection for at least 48 weeks - Stable but suboptimal CD4 recovery over previous year (<250 cells/mm3 and slope of annual change between -20 and 20 cells/mm3) - No prior exposure to a CCR5 antagonist MVC + Suppressive ART (n = 34) Single Treatment Arm - Maraviroc added to ART for 24 weeks, then stopped and patient followed another 24 weeks Source: Wilkin TJ, et al. J Infect Dis. 2012;206:534-42.
Adding Maraviroc to Suppressive ART for Suboptimal CD4 Recovery ACTG 5256: Results Change in CD4 Count with Maraviroc Intensification 20 Median change in CD4 (cells/mm3) Maraviroc added Maraviroc stopped 15 10 5 0 0 4 8 12 16 24 36 48 Weeks *The median increase in CD4(+) T-cell count from baseline to week 24 was 12 cells/mm3. Source: Wilkin TJ, et al. J Infect Dis. 2012;206:534-42.
Adding Maraviroc to Suppressive ART for Suboptimal CD4 Recovery ACTG 5256: Conclusions Conclusions: Adding maraviroc to suppressive ART for 24 weeks was not associated with an increase in CD4+T-cell counts of at least 20 cells/mm3. Further studies of CCR5 antagonists in the dampening of immune activation associated with HIV infection are warranted. Source: Wilkin TJ, et al. J Infect Dis. 2012;206:534-42.
Acknowledgment The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center. The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.
![[Insert Study Name] Study Webinar: Engaging Participants for Research Progress](/thumb/168084/insert-study-name-study-webinar-engaging-participants-for-research-progress.jpg)
